Up to 50 percent of people with Graves disease develop thyroid eye disease: eyes bulge forward, vision doubles, in severe cases sight is lost. For the chronic phase of this condition, in which hundreds of thousands of patients globally live, there was no systemic therapy. That changed June 26, 2026: the FDA approved Lumvoa (Veligrotug-vvze) by Viridian Therapeutics, the first medication with clinical trial data for both active and chronic disease.
Why the Disease Is So Hard to Treat
Thyroid eye disease (TED) is an autoimmune condition of the eye socket. The immune system attacks orbital tissue, causing glycosaminoglycans and fat to accumulate behind the eyeball. The eye is pushed forward. In severe cases, eyelids cannot fully close. Diplopia, double vision, occurs when eye muscles are unevenly affected.
The disease progresses in two phases: an active phase with acute inflammation typically lasting 18 to 24 months, and a chronic phase with established structural changes. A meta-analysis in Clinical Endocrinology found TED affects roughly 2.9 to 4.5 per 10,000 people globally, with European incidence around 19 new cases per 100,000 annually.
Until 2020 there was no FDA-approved systemic therapy. Corticosteroids temporarily dampened inflammation, surgical decompression was the only long-term option in severe cases. Teprotumumab, the first monoclonal antibody, arrived with a restricted indication: active TED only. Patients past the active phase who still suffered double vision or eye bulging had no drug option.
What Makes Lumvoa Different
Both drugs target the same receptor: IGF-1R, the insulin-like growth factor-1 receptor, overexpressed on orbital fibroblasts and central to the inflammatory cascade. The mechanism difference: teprotumumab is a partial IGF-1R antagonist. Veligrotug is described as a complete antagonist, blocking both proximal and distal signaling. Without a head-to-head trial, clinical relevance of this difference remains unclear.
A practical difference is the treatment schedule. Lumvoa requires five IV infusions every three weeks over twelve weeks. Teprotumumab requires eight infusions over 21 weeks, nearly double the time. Lumvoa's shorter schedule may reduce treatment burden for patients.
What the THRIVE Studies Showed
FDA approval rests on two Phase 3 trials. In THRIVE (active TED), 70 percent of veligrotug-treated patients achieved clinically meaningful proptosis reduction (vs 5 percent placebo). Forty-nine percent showed complete diplopia resolution, compared with 12 percent on placebo.
THRIVE-2 examined the chronic phase: patients with average disease duration of 69.8 months, nearly six years. Fifty-six percent of treated patients achieved proptosis improvement (vs 8 percent placebo), 32 percent complete diplopia resolution (vs 14 percent placebo). The FDA specifically noted in its approval that Lumvoa is indicated for TED regardless of disease activity or duration. It is the first drug in its class with such a broad indication.
In Comparison: Other Rare Eye Disease Breakthroughs
TED is not alone in lacking approved therapies for years. Leber congenital amauros type 2, an inherited blindness disorder, was considered incurable until 2017: Luxturna (Voretigene neparvovec) became the first gene therapy for inherited retinal disease approved by the FDA. This represented roughly 15 years of development. For age-related macular degeneration (AMD), the span from identifying VEGF as a target (1989) to approving ranibizumab (Lucentis, 2006) was 17 years.
Two IGF-1R inhibitors approved for TED within six years (2020 to 2026) is unusually rapid for a rare eye disease. European approval remains pending: Viridian has submitted an EMA application.
Three Conditions for Patients to Actually Access It
First condition: coverage. Teprotumumab costs roughly 220,000 to 250,000 dollars per treatment cycle in the US, among the most expensive drugs ever. Veligrotug has no public US list price; European pricing is unknown. Without insurance coverage, the drug remains out of reach for most patients even in well-funded health systems.
Second condition: long-term data. THRIVE studies measure outcomes over twelve weeks. How long benefit lasts, how often relapses occur, and which long-term side effects emerge remains unknown. For a chronic condition lasting decades, this is a critical information gap that follow-up studies must close.
Third condition: earlier diagnosis. Many TED patients are diagnosed with delay because early symptoms are mistaken for eye fatigue or allergy. Even an effective drug helps most in the active phase. Lumvoa is the first to address this partially, working in chronic disease. Whether this actually leads to earlier diagnosis in practice or whether diagnostic delays persist will show in post-marketing studies.